Abstract
Human embryonic stem cells have virtually limitless use and enormous potential for therapeutic medicine. However, the lack of common technical standards and uniform patent criteria have hampered further technological progress. For human embryonic stem cell research in the European Union (EU), the divergent regulations among member states have generated unequal access to treatment and an imbalance in distribution of benefits and duties.
| Original language | English |
|---|---|
| Pages (from-to) | 63-69 |
| Number of pages | 7 |
| Journal | Intellectual Property Forum |
| Issue number | 97 |
| Publication status | Published - 30 Jun 2014 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Space for Flexibilitiy: Lessons from the European Union Harmonisation Model in Human Embryonic Stem Cell Regulation'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver